Amylin Gets TRO Against Lilly
A San Diego federal court granted a temporary restraining order sought by San Diego diabetes drug developer Amylin Pharmaceuticals (NASDAQ: AMLN) against Eli Lilly. Amylin sued Lilly a few week ago for violating their joint marketing agreement for exenatide. The court ordered Lilly to halt its plans to use the same sales force to sell both Amylin’s exenatide and linagliptin, a rival diabetes drug from Germany’s Boehringer Ingelheim. The order also prohibits Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees who are marketing linagliptin.